Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close. The company is a clinical-stage small molecule precision medicine firm focused on oncology and genetic-disease therapies.
Relay Therapeutics (Nasdaq: RLAY)/b) reported clinical data supporting advancement of into a planned Phase 3 frontline trial for PIK3CA‑mutated, HR+/HER2‑ metastatic breast cancer, targeting initiation in early 2027 pending regulatory feedback.
Key data: 44% ORR (15/34 measurable patients) in median third‑line, 3% zovegalisib discontinuation, 40% grade 3+ TRAE rate, and a pharmacokinetic interaction increasing zovegalisib exposure ~2.5‑fold. Pfizer will supply atirmociclib for the trial.
Relay Therapeutics (Nasdaq: RLAY) will present initial clinical and preclinical data for zovegalisib (RLY-2608) in vascular anomalies at the ISSVA World Congress 2026 in Philadelphia, May 19-22, 2026.
The company expects to report clinical data on approximately 20 efficacy-evaluable patients in a Late Breaking Abstract on May 20, 2026, and will present preclinical murine-model results showing lesion regression with minimal hyperinsulinemia on May 22, 2026. Presentations will be posted on the company website at session start times.
Relay Therapeutics (Nasdaq: RLAY) reported Phase 1/2 ReDiscover data for zovegalisib 400mg BID fed plus fulvestrant in PI3Kα‑mutated, HR+/HER2‑ metastatic breast cancer. Among 57 efficacy‑evaluable patients (data cut‑off Jan 13, 2026) median PFS was 11.1 months (95% CI: 7.3–13.0); ORR was 43% in 35 measurable patients. Pharmacokinetics showed 400mg fed exposures comparable to 600mg fasted. Safety was mainly low‑grade TRAEs; four discontinuations. Zovegalisib has FDA Breakthrough Therapy designation and the Phase 3 ReDiscover‑2 trial is ongoing.
Relay Therapeutics (Nasdaq: RLAY) reported Q4 and full-year 2025 results and outlined 2026 clinical milestones for zovegalisib. Key financials: $554.5M cash and investments at 12/31/25, $15.4M 2025 revenue, and $276.5M net loss for 2025. Clinical highlights include FDA Breakthrough Therapy designation, ESMO TAT presentation on March 16, 2026, and planned 1H 2026 data in PIK3CA-driven vascular anomalies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two investor fireside chats in March 2026. Management will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 10:30 a.m. ET.
Both sessions will be webcast live and archived replays will be available for up to 30 days via the company's Events page.
Relay Therapeutics (Nasdaq: RLAY) will report its fourth quarter and full year 2025 financial results and corporate highlights after U.S. market close on February 26, 2026. The company is a clinical-stage small molecule precision medicine firm focused on cancer and genetic disease therapies.
Relay Therapeutics (Nasdaq: RLAY) announced management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The session will be webcast live and an archived replay will be available for up to 30 days.
Investors can access the live and archived webcast via Relay Therapeutics’ Events page on its investor website.
Relay Therapeutics (Nasdaq: RLAY) announced the U.S. FDA granted Breakthrough Therapy designation to zovegalisib (RLY-2608) plus fulvestrant for adults with PIK3CA-mutant, HR+/HER2- locally advanced or metastatic breast cancer after progression on a CDK4/6 inhibitor.
BTD was supported by Phase 1/2 ReDiscover data including two comparable-dose cohorts: 600mg BID fasted (N=52) and 400mg BID fed (N=57), with 400mg BID as the Phase 3 dose; 400mg fed data will be presented March 16, 2026.
Relay Therapeutics (Nasdaq: RLAY) reported subset efficacy from its ReDiscover program for zovegalisib (RLY-2608) + fulvestrant presented at SABCS 2025. In a 52-patient efficacy cohort (600mg BID fasted, no PTEN/AKT co-mutation; data cut-off Oct 15, 2025; median follow-up 20.2 months), median PFS was 10.3 months overall and 11.4 months in 2L patients. Among 31 patients with measurable disease, ORR was 39% (47% in 2L). Prior SERD patients showed PFS 11.4 months (ORR 44%); ESR1-mutant patients showed PFS 8.8 months (ORR 60%). Safety remained mostly low-grade and manageable.